Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Acquired_by_Madrigal_Pharmaceuticals
|
| gptkbp:businessModel |
Research and development
Biopharmaceutical development Commercialization of drugs |
| gptkbp:CEO |
gptkb:Safi_Bahcall
|
| gptkbp:clinicalTrials |
Cancer treatment
Drug development Therapeutic development Phase 2 trial for Hsp90 inhibitors Phase 3 trial for elesclomol |
| gptkbp:financials |
Publicly traded
Market capitalization Listed_on_NASDAQ |
| gptkbp:focusesOn |
cancer therapeutics
|
| gptkbp:founded |
2007
|
| gptkbp:funding |
Venture capital funding
|
| gptkbp:headquarters |
gptkb:Lexington,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Synta Pharmaceuticals, LLC
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:investmentFocus |
Institutional investors
Private equity firms Venture capital firms |
| gptkbp:keyPeople |
gptkb:Safi_Bahcall
gptkb:Richard_A._Miller gptkb:David_M._Hyman |
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
Global market
European_market North_American_market Asian_market |
| gptkbp:notableEvent |
gptkb:elesclomol
|
| gptkbp:partnerships |
Collaboration_with_AstraZeneca
Collaboration_with_Merck Collaboration_with_Pfizer |
| gptkbp:products |
Oncology drugs
Investigational drugs Therapeutic_agents |
| gptkbp:regulatoryCompliance |
EMA_approval_for_elesclomol
FDA_approval_for_elesclomol |
| gptkbp:researchFocus |
small molecule drugs
Hsp90 inhibitors |
| gptkbp:researchInterest |
Collaboration with academic institutions
Collaboration with research organizations |
| gptkbp:subsidiary |
gptkb:Synta_Pharmaceuticals,_Inc.
|
| gptkbp:targetMarket |
Oncology specialists
Healthcare_providers Cancer_patients |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:type |
Public company
|
| gptkbp:website |
www.syntapharma.com
|